These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8152324)

  • 1. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure.
    Gao XP; Noda Y; Rubinstein I; Paul S
    Life Sci; 1994; 54(15):PL247-52. PubMed ID: 8152324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ.
    Suzuki H; Noda Y; Gao XP; Séjourné F; Alkan-Onyuksel H; Paul S; Rubinstein I
    Am J Physiol; 1996 Jul; 271(1 Pt 2):H282-7. PubMed ID: 8760186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulation of vasoactive intestinal peptide into liposomes: effects on vasodilation in vivo.
    Suzuki H; Noda Y; Paul S; Gao XP; Rubinstein I
    Life Sci; 1995; 57(15):1451-7. PubMed ID: 7674836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
    Rubinstein I; Ikezaki H; Onyüksel H
    Int J Pharm; 2006 Jun; 316(1-2):144-7. PubMed ID: 16580160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch.
    Ikezaki H; Paul S; Alkan-Onyüksel H; Patel M; Gao XP; Rubinstein I
    Am J Physiol; 1998 Jul; 275(1):R56-62. PubMed ID: 9688960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension.
    Onyüksel H; Séjourné F; Suzuki H; Rubinstein I
    Peptides; 2006 Sep; 27(9):2271-5. PubMed ID: 16621151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes.
    Séjourné F; Rubinstein I; Suzuki H; Alkan-Onyüksel H
    Pharm Res; 1997 Mar; 14(3):362-5. PubMed ID: 9098882
    [No Abstract]   [Full Text] [Related]  

  • 8. Liposomal VIP potentiates DNA synthesis in cultured oral keratinocytes.
    Rubinstein I; Dagar S; Sethi V; Krishnadas A; Onyüksel H
    Peptides; 2001 Apr; 22(4):671-5. PubMed ID: 11311738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal vasoactive intestinal peptide.
    Sethi V; Onyüksel H; Rubinstein I
    Methods Enzymol; 2005; 391():377-95. PubMed ID: 15721392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo.
    Séjourné F; Suzuki H; Alkan-Onyüksel H; Gao XP; Ikezaki H; Rubinstein I
    Am J Physiol; 1997 Jul; 273(1 Pt 2):R287-92. PubMed ID: 9249562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of vasoactive intestinal peptide by lipids.
    Gololobov G; Noda Y; Sherman S; Rubinstein I; Baranowska-Kortylewicz J; Paul S
    J Pharmacol Exp Ther; 1998 May; 285(2):753-8. PubMed ID: 9580623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity.
    Onyüksel H; Ashok B; Dagar S; Sethi V; Rubinstein I
    Peptides; 2003 Feb; 24(2):281-6. PubMed ID: 12668213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of liposomal 131I-VIP in rat using gamma camera.
    Refai E; Jonsson C; Andersson M; Jacobsson H; Larsson S; Kogner P; Hassan M
    Nucl Med Biol; 1999 Nov; 26(8):931-6. PubMed ID: 10708307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal VIP attenuates phenylephrine- and ANG II-induced vasoconstriction in vivo.
    Ikezaki H; Onyüksel H; Rubinstein I
    Am J Physiol; 1998 Aug; 275(2):R588-95. PubMed ID: 9688697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin.
    Rubinstein I; Patel M; Ikezaki H; Dagar S; Onyüksel H
    Peptides; 1999 Dec; 20(12):1497-501. PubMed ID: 10698126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intracerebroventricular injection of vasoactive intestinal polypeptide on systemic blood pressure and pancreatic and gastric secretions in the rat.
    Mizuta K; Moriga M; Narusawa H; Uchino H; Aono M
    Gastroenterol Jpn; 1986 Feb; 21(1):55-61. PubMed ID: 3699399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of vasoactive intestinal peptide (VIP) on the testicular vasculature of the rat.
    Lissbrant E; Bergh A
    Int J Androl; 1997 Dec; 20(6):356-60. PubMed ID: 9568528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.
    Lajavardi L; Bochot A; Camelo S; Goldenberg B; Naud MC; Behar-Cohen F; Fattal E; de Kozak Y
    Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):3230-8. PubMed ID: 17591893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles.
    Ashok B; Rubinstein I; Tsueshita T; Onyüksel H
    Peptides; 2004 Aug; 25(8):1253-8. PubMed ID: 15350692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of intravitreal injection of vasoactive intestinal peptide-loaded liposomes on experimental autoimmune uveoretinitis.
    Camelo S; Lajavardi L; Bochot A; Goldenberg B; Naud MC; Brunel N; Lescure B; Klein C; Fattal E; Behar-Cohen F; de Kozak Y
    J Ocul Pharmacol Ther; 2009 Feb; 25(1):9-21. PubMed ID: 19232006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.